Fig. 4: Immunotherapy biomarker correlation of PD-L1 IHC, MSI, TMB, and CD274 gene amplification. | Modern Pathology

Fig. 4: Immunotherapy biomarker correlation of PD-L1 IHC, MSI, TMB, and CD274 gene amplification.

From: A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

Fig. 4

a When comparing CD274 gene amplification with PD-L1 IHC, prevalence was significantly higher (1.56%, 310/19,856) in the PD-L1 positive cohort and lower in the PD-L1 negative cohort (0.14%, 40/28,926) (Fisher’s exact test, p < 0.0001). b The prevalence of MSI-H was also significantly higher at 8.83% (907/10,273) in the TMB ≥ 10 mutations/Mb when compared to 0.05% (18/38,509) in the TMB < 10 mutations/Mb cohort (Fisher’s exact test, p < 0.0001). c No significant difference was found in MSI-H prevalence between the PD-L1 IHC negative and positive groups (Fisher’s exact test, p = 0.457). d A significantly higher TMB positive rate (28.5%, 5650/19,856) in the PD-L1 positive group when compared to the PD-L1 negative group was present (16.0%, 4623/28,926) (Fisher’s exact test, p < 0.0001). e The prevalence of TMB−/PD-L1−, TMB+/PD-L1–, TMB−/PD-L1+, TMB+/PD-L1+ cohorts were dependent on tumor type.

Back to article page